Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Vorinostat,VORI1001,2021,USA,MDV,350,68,45,55,27.5,32,85,12,15,30,40,15,55,25,15,5,20,35,45,18,8,5,10,7,22,38,45,CHOP,EPOCH,R-CHOP,R-CVP,5,3,2,25,60,70,15,55,30,65,2
Vorinostat,VORI1002,2022,Canada,Claim Database,420,72,48,52,28.1,28,82,15,12,28,42,18,52,28,14,6,18,32,50,20,10,6,12,8,25,40,48,CHOP,ICE,R-CHOP,Bendamustine,6,4,3,28,65,75,12,58,30,70,2.5
Vorinostat,VORI1003,2023,UK,MDV,280,65,52,48,26.8,35,88,10,18,32,38,12,58,22,14,6,22,38,40,16,7,4,9,6,20,35,42,CHOP,DHAP,R-CHOP,Rituximab,4,2,1,22,55,65,18,52,30,60,1.8
